Biogen to Initiate Phase 4 Study Evaluating Benefit of Spinraza® in Patients Treated With Zolgensma®

21 July 2020

Biogen have announced today that it plans to initiate a global Phase 4 clinical study, called RESPOND, to examine the clinical benefit, and assess the safety, of Spinraza® 
(nusinersen) in infants and children who have SMA, who still have unmet clinical needs following treatment with the gene therapy treatment Zolgensma® (onasemnogene abeparvovec).

The study is projected to enroll 60 children up to age 3 who are determined by the investigator to have the potential for additional clinical improvement after receiving Zolgensma®.

Biogen have provided an update to the Community about this with further information:

Read the community update

Information about nusinersen